FDA approval of the first drug for NASH treatment
Nonalcoholic steatohepatitis (NASH) is a common form of liver inflammation that is causing concern worldwide. This chronic disease is often linked with obesity and type 2 diabetes, making it a significant health issue in today's society. However, the recent FDA approval of the first drug for NASH treatment offers a glimmer of hope for millions suffering from this condition.
Liver inflammation, also known as hepatitis, is a condition that can be caused by various factors such as viruses, alcohol abuse, and autoimmune diseases. However, one of the most common forms of hepatitis is non-viral and is related to lifestyle factors - Nonalcoholic Steatohepatitis (NASH).
NASH is a severe form of nonalcoholic fatty liver disease (NAFLD), characterized by excessive fat accumulation in the liver...